Scientific Organising Committee
- Prof. Sandrine Faivre
- Prof. Tom Luedde
- Prof. Maria Reig
Welcome Message
Dear Colleagues,
We would like to cordially invite you to the third EASL Hepatocellular Carcinoma (HCC) Summit: From basic to clinical research: How to improve HCC clinical care? to be held in Geneva, Switzerland from 1-3 March 2018.
HCC is considered one of the most important causes of death in patients affected with chronic liver disease. In the past years, major advances in the early diagnosis and treatment, particularly in advanced stages, have taken place.
This Summit will cover both the basic and translational/clinical aspects of the disease, with a specific focus on new targeted therapies in HCC. Great efforts have been made in the scientific programme to enhance the interaction among basic scientists, clinical researchers, and Industry leaders to stimulate our combined efforts in addressing the key challenges in HCC.
This year’s programme will be informative and stimulating, covering a broad range of topics presented as high-quality presentations by renowned experts. We anticipate that this combination of high quality and interactive presentations by leading scientists and clinicians from academia and industry will be successful, and will help to move the field forward.
We are eager to welcome you in Geneva for this major event.
Sincerely,
The Scientific Committee
Why attend?
- 3 days of cutting edge basic and clinical research on liver cancer
- Latest in clinical care and patient management
- Showcase your research, gather and network with renowned scientists and leading exper
Who should attend?
- Hepatologists
- Physicians with interest in liver cancer
- Young researchers and trainees
- Basic and translational scientists
- Clinical researchers
- Health professionals
- Industry
Topic to be covered
- Patient management
- Epidemiology
- Diagnostic challenges
- Systemic treatments
- Immunotherapy
- Surgical and locoregional therapies
- Biomarkers
- Tumor diversity
- Single cell approaches
- New targeted therapies
- Industry perspective
Acknowledgements
EASL thanks its Premium Sponsors AbbVie and MSD for their generous contribution and support of the association’s activities with unrestricted educational grants.
AbbVie and MSD have had no input into the content of the materials and presentations used at this event.
Help us to inform the liver community by downloading the poster, printing it and placing it on your institute's notice board or forwarding it to your local network:
Download Poster